Comparative Pharmacology
Head-to-head clinical analysis: FURADANTIN versus MACROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURADANTIN versus MACROBID.
FURADANTIN vs MACROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial enzymes involved in cell wall synthesis, DNA replication, and RNA transcription. It is bactericidal against susceptible organisms.
Nitrofurantoin is a urinary tract antibacterial agent that inhibits bacterial acetyl-CoA carboxylase, disrupting cell wall synthesis and bacterial respiration. It is reduced by bacterial nitroreductases to reactive intermediates that damage DNA, ribosomes, and other macromolecules.
100 mg orally twice daily for 5-7 days; acute uncomplicated cystitis: 50 mg four times daily or 100 mg twice daily for 5 days.
100 mg orally twice daily with food for 7 days.
None Documented
None Documented
Terminal elimination half-life is 0.3-1 hour in adults with normal renal function; prolonged to 1-4 hours in renal impairment (creatinine clearance <60 mL/min) and may exceed 20 hours in anuria.
Terminal elimination half-life: 0.3-1.0 hour (short) due to rapid renal clearance and tissue metabolism; no accumulation with twice-daily dosing. The short half-life is adequate for urinary tract exposure.
Renal: 36% (glomerular filtration and tubular secretion); fecal: 40-50% (biliary excretion and unabsorbed drug); hepatic metabolism: minor (acetylation and reduction) accounting for <10%.
Renal: 36% (unchanged nitrofurantoin) and 15% (metabolites) within 24 hours. Total renal elimination: 51%. Biliary/fecal: 1-2%. Additional 30% undergoes rapid metabolic degradation in tissues.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective